Sareum (LON:SAR) Posts Quarterly Earnings Results

Sareum (LON:SAR) announced its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.

Sareum Stock Performance

Shares of SAR stock traded up GBX 1.25 ($0.02) during mid-day trading on Thursday, hitting GBX 13.25 ($0.17). The company’s stock had a trading volume of 1,291,784 shares, compared to its average volume of 426,124. Sareum has a 52-week low of GBX 10 ($0.13) and a 52-week high of GBX 52.50 ($0.68). The stock has a market cap of £16.55 million, a price-to-earnings ratio of -3.14 and a beta of -1.08. The business has a 50-day moving average price of GBX 17.82 and a 200 day moving average price of GBX 23.19.

Insider Buying and Selling

In related news, insider Stephen Parker bought 84,033 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of GBX 12 ($0.15) per share, for a total transaction of £10,083.96 ($12,983.08). 5.02% of the stock is owned by corporate insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.